NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc. (“XBiotech”) (NASDAQ:XBIT) concerning possible violations of federal securities laws.
On April 20, 2017, XBiotech announced that the European Medicines Agency (“EMA”) had rendered a negative trend vote after meeting with the Company to discuss its marketing authorization application (“MAA”) for XBiotech's candidate antibody for the treatment of colorectal cancer. Then on May 18, 2017, XBiotech announced it had received a negative opinion for its MAA. Then on June 9, 2017, XBiotech announced it had discontinued a Phase 3 study for the treatment after the findings “were not sufficient to meet efficacy or the threshold for continuation.” To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.